MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-023-42324-6

Медицинская библиотека · Scientific reports · 2023

Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis.

Inoue Mariko, Nagafuchi Yasuo, Ota Mineto, Tsuchiya Haruka, Tateishi Shoko, Kanda Hiroko, Fujio Keishi

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

HLA-DRB1 shared epitope risk alleles are the strongest genetic risk factors for rheumatoid arthritis (RA) and potential biomarkers for treatment response to biological disease-modifying antirheumatic drugs (bDMARDs). This study aimed to investigate the association between treatment response and individual HLA-DRB1 alleles in RA patients receiving different bDMARDs. We recruited 106 patients with active RA who had started abatacept, tocilizumab, or TNF inhibitors as a first-line bDMARDs. We examined the relationship between Simplified Disease Activity Index (SDAI) improvement at 3 months and HLA-DRB1 allele carriage. The results revealed that the HLA-DRB1*04:05 allele, a shared-epitope allele, was significantly associated with better SDAI improvement only after abatacept treatment (SDAI improvement 28.5% without the allele vs 59.8% with allele, p = 0.003). However, no significant association was found with other treatments. Both multivariate linear regression and mediation analysis confirmed that the HLA-DRB1*04:05 allele was independently associated with abatacept treatment response, regardless of anti-CCP antibody titers. The study concluded that in patients with RA receiving their first-line bDMARD treatment, carrying the HLA-DRB1*04:05 allele was associated with better SDAI improvement specifically in abatacept-treated patients. These disease-risk HLA alleles have the potential to serve as genomic biomarkers for predicting treatment response with co-stimulation blockage therapy.

Для цитирования: Inoue Mariko, Nagafuchi Yasuo, Ota Mineto, Tsuchiya Haruka, Tateishi Shoko, Kanda Hiroko, Fujio Keishi. Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis.. Scientific reports. 2023. DOI: 10.1038/s41598-023-42324-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.